Back

GLP-1 RA vs DPP4i in patients with prior major adverse limb evets

30 August 2025 (13:15 - 14:00)
Organised by: Logo
Congress Presentation Part of: Adjuvant strategies to peripheral artery disease Pharmacotherapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Ms Ching Jung Chen

Linkou Chang Gung Memorial Hospital, Tao-Yuan (Taiwan)

6 More presentations in this session

Presentation thumbnail
Effectiveness and safety of rivaroxaban vs apixaban in patients with Atrial Fibrillation and Peripheral Artery Disease
Doctor L. Dari (Bordeaux, FR)
Abstract Slides Video
Presentation thumbnail
Association of baseline and longitudinal changes in non-high-density lipoprotein cholesterol/high-density lipoprotein cholesterol ratio with cardiovascular outcomes in peripheral artery disease
Doctor Z. Liu (Sha Tin, HK)
Abstract Slides Video
Presentation thumbnail
Contemporary treatment patterns and outcomes of endovascular therapy in octogenarians and older with peripheral artery disease: a multicentric analysis of 1980 patients from the RECCORD registry
Doctor D. Pinsdorf (Essen, DE)
Abstract Slides Video
Presentation thumbnail
Serum ferritin level could predict wound healing in chronic limb-threatening ischemia patients after endovascular therapy
Doctor J. Nakamura (Osaka, JP)
Abstract Slides Video
Presentation thumbnail
Effect of behaviour change interventions on walking capacity, clinical outcomes, and quality of life in intermittent claudication: insights from the OPTIMA systematic review and meta-analysis
Doctor U. Abaraogu (Enugu, NG)
Abstract Slides Video

Access the full session

Session thumbnail
Adjuvant strategies to peripheral artery disease

The Event

Event poster

ESC Congress 2025

30 August 2025 13:15 CET
You may be interested in
thumbnail
Congress Presentation
GLP-1 RAs reduce mortality and cardiovascular events across the spectrum of treated patients: a systematic review and meta-analysis
thumbnail
Congress Presentation
The effect of Glucagon-like peptide-1 receptor agonists on cardiovascular outcomes in type 2 diabetes mellitus patients with coronary artery disease
thumbnail
Congress Session
Repurposing anti-diabetic pharmacotherapy: the new cure for all evils?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources